Commentary: Chronic Lymphocytic Leukemia—The Price of Progress-Reference-Cited by-同舟云学术

Commentary: Chronic Lymphocytic Leukemia—The Price of Progress

Published:2010-05-12 Issue:6 Volume:15 Page:601-602
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Shanafelt Tait D.¹,Gunderson Heidi¹,Call Timothy G.¹

Affiliation:

1. Mayo Clinic; Rochester, Minnesota, USA

Abstract

The study looks at the high cost of new treatments for chronic lymphocytic leukemia and calls for the consideration of a standardized and transparent method to determine the price of new drugs based on comparative effectiveness.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2010-0090

Reference6 articles.

1. Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL);Rai;Blood,2009

2. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group;Hallek;Blood,2009

3. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

4. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712);Byrd;Blood,2003

5. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia;Kay;Blood,2007

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty;Current Hematologic Malignancy Reports;2018-07-07

2. Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective;European Journal of Haematology;2016-11-01

3. Exploring Big Data in Hematological Malignancies: Challenges and Opportunities;Current Hematologic Malignancy Reports;2016-05-13

4. Nanotechnology applications in hematological malignancies (Review);Oncology Reports;2015-07-02

5. Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels;Journal of Oncology Practice;2015-05